Curated News
By: NewsRamp Editorial Staff
March 04, 2025

ADAP Advocacy Report Exposes Disparity in 340B Drug Pricing Program

Reddit Discuss on RedditDiscuss on LinkedIn LinkedInDiscuss on Substack SubstackDiscuss on Telegram TelegramView History of this news story on GitHub Github
Source News Release

TLDR

  • Executives of 340B-eligible entities saw a 237.11% increase in compensation, providing a significant advantage in financial growth.
  • The report on the 340B Drug Pricing Program reveals a detailed analysis of annual revenue and executive compensation trends.
  • The 340B Program aims to benefit patients, but the report highlights the need to prioritize patient care over executive compensation and profit.
  • The 340B Executive Compensation Report sheds light on discrepancies in charity care provision and revenue increases among covered entities.

Impact - Why it Matters

This news sheds light on the potential misalignment of priorities within the 340B Program, raising questions about patient care versus financial gains. The findings underscore the need for transparency and accountability in healthcare organizations to ensure that the program benefits those it was intended to serve.

Summary

ADAP Advocacy and the Community Access National Network (CANN) released a supplemental report on the 340B Drug Pricing Program, revealing significant increases in covered entities' annual revenues and executive compensation. The report highlighted a concerning trend where patient copayments are not reimbursed, while executives see substantial pay raises.

Source Statement

This curated news summary relied on this press release disributed by 24-7 Press Release. Read the source press release here, ADAP Advocacy Report Exposes Disparity in 340B Drug Pricing Program

blockchain registration record for the source press release.